Amol Akhade: Landscape for urothelial carcinoma treatment is rapidly evolving
Amol Akhade shared on X:
“The landscape for urothelial carcinoma treatment is rapidly evolving. Now we have a first positive trial with Neoadjuvant and Adjuvant IO to improve EFS and OS in muscle invasive bladder cancer.
NIAGARA trial for Durvalumab. Remember Ambassador trial ( adjuvant Pembrolizumab did not show OS ) Adjuvant Nivolumab did show OS benefit ( checkmate 274 ) Other IO are being tested in both neoadjuvant and Adjuvant Setting.
It will be interesting to see how much additional benefit such neo adjuvant IO gives? What will be treatment on progression for these patients? Interesting to see full data.”
Source: Amol Akhade/X
Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist. He has received his super specialization training in hemato-oncology and medical oncology from Tata memorial hospital. He specialises in chemotherapy for hematological cancers as well as solid tumors.
He also specialises in allogenic and autologous bone marrow transplant. Currently he is a Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023